Artificial intelligence (AI) and emerging technologies are bringing exciting changes to hospitals and health systems. In recent years, with advances in technology, healthcare organizations have increasingly adopted digital health solutions to improve patient care. For example, providers are using clinical decision support (CDS) platforms to optimize treatments to help ensure that drugs work as expected. The precise dose CDS platform incorporates artificial intelligence, enabling hospitals to reduce medication errors, improve the quality of care, and save costs in 2021 and beyond.
Accurate dosage specific to the hospital environment
Precise dosing is defined as the process of individualizing the dosage of drugs by taking into account specific patient factors such as demographics, clinical characteristics, and genetic data. The precise dose CDS platform is a key tool to reduce Adverse Drug Events (ADE), some of the most expensive medical complications that add more than $30 billion to the U.S. healthcare system each year. ADE also results in 1.3 million visits to the emergency department each year, according to CDC. Ultimately, ADE will cause many negative downstream effect For patients, this includes longer hospital stays, more emergency visits, and higher admission and readmission rates.
Many patients are at risk of ADE because drugs are usually developed for ordinary patients. During the clinical development program, drugs are usually studied in thousands of patients. Therefore, many types of patients have not been fully studied in clinical trials, including elderly patients, pediatric patients, and patients with end-organ dysfunction. This has downstream implications because once the drug is approved, it will usually be used more widely in under-characterized patient populations in clinical trials. These patient groups are at higher risk of adverse clinical outcomes.In fact, the FDA has reported that drugs across a range of therapeutic areas are only 25% to 62% Of patients. Precision dosing has the ability to solve these two problems through personalized dosing.
Precise administration is especially beneficial for drugs with a narrow therapeutic window (that is, drugs whose toxic dose is very close to the minimum dose required for the drug to be effective). This method may also be beneficial for drugs with high variability in drug response between patients. Key therapeutic areas for precise doses include infectious diseases, oncology, blood and bone marrow transplantation, solid organ transplantation, and inflammatory bowel disease. For example, in the individualized administration of vancomycin, the precise administration effect is very good. Vancomycin is an antibiotic used to treat bacterial infections. If the dose is too high, it will cause acute kidney injury, which will lead to longer hospital stays and longer hospital stays. The cost is higher.
Today, hospital doctors and pharmacists are incorporating precise dosages into their clinical practice to ensure that patients receive the correct doses of complex drugs, from intravenous antibiotics to chemotherapy. Hospital clinicians can access precise dosing guidance through the EHR integrated application integrated into their clinical workflow or through a stand-alone web-based application.
Modern precision drug delivery support platforms use pharmacological models and machine learning to operate on patient-specific data (including demographics, clinical, laboratory, and genetic information) to help clinicians understand the patient’s individual pharmacological characteristics and provide guidance Drug decision. The goal is to ensure that every patient receives the right dose at the right time.Accurate dosing possible Already applied By ensuring that patients receive the maximum effective dose, while reducing the possibility of adverse drug events to improve the patient’s treatment effect.
What is the outlook for 2021 and beyond?
With advances in artificial intelligence and machine learning and precision dosing technology becoming more and more available at the point of care, we are seeing healthcare continue to shift from a fixed-dose mindset to a mindset that embraces personalized doses. We also hope to see an increase in the precise dosage and monitoring of special drugs, as well as conditioning programs for gene therapy and cell therapy.
Driven by the recently revised Vancomycin Dosing Consensus, point-of-care personalized treatment with precise dosing and drug monitoring is also gaining momentum GuidelinesThe new guidelines call for the use of Bayesian drug delivery software to transform vancomycin monitoring based solely on serum trough levels into area under the curve (AUC)-guided drug delivery. The software adapts to different treatment options and individual patient physiology. The change in the treatment process.
In addition to precise drug delivery at the point of care, we will also see greater utility in the drug development process. Biopharmaceutical companies are increasingly incorporating precise doses into clinical trials, and are motivated to bundle precise doses with new drugs used to treat rare and common diseases to maximize the effectiveness of new therapies. This means that once a drug is approved, clinicians may benefit from the immediate availability of CDS tools, which can help determine individualized dosing regimens for newly approved drugs.
At the same time, large hospitals and health systems may also benefit from the ability to tailor pharmacological models to specific patient groups. Currently, precision drug delivery platforms use pharmacokinetic models derived from general population data to guide drug delivery decisions. Health systems whose patient populations are not very similar to the general population on which the models are based may find that the dosing regimens recommended by these models are not accurate and may increase the time it takes for the patient to reach the target drug exposure.
In the near future, provider organizations will be able to use retrospective data from their patient populations to develop predictive models tailored to their patient demographics to achieve more accurate drug delivery in their populations. Using more accurate, population-specific precise dosage models will help organizations improve the quality of care and reduce costs as they increasingly transition to value-based care and risk-based contracts.
As artificial intelligence enters more areas of healthcare services, precision medicine will be redefined, and its benefits will extend to more patients.Precision medicine no longer just means choosing targeted drugs for patients with specific genomic characteristics-this approach is considered in oncology Only about 5% of cancer patients benefit. Precision medicine will develop to include personalized delivery of a wide range of drugs that have been widely used in many therapeutic areas. Precision medicine, including precision drug delivery, not only has positive significance for patients, but is also expected to improve the operating business model of hospitals and health systems, reduce payment costs, and improve clinical research and drug development.
Photo: Stas_V, Getty Images
